Luigino Dal Maso1, Chiara Panato1, Andrea Tavilla2, Stefano Guzzinati3, Diego Serraino1, Sandra Mallone2, Laura Botta4, Olayidé Boussari5, Riccardo Capocaccia6, Marc Colonna7, Emanuele Crocetti8, Agnes Dumas9, Tadek Dyba10, Silvia Franceschi1, Gemma Gatta4, Anna Gigli11, Francesco Giusti10, Valerie Jooste5, Pamela Minicozzi12,13, Luciana Neamtiu10, Gaëlle Romain5, Manuel Zorzi3, Roberta De Angelis14, Silvia Francisci2. 1. Cancer Epidemiology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy. 2. National Center for Prevention and Health Promotion, Italian National Institute of Health (ISS), Rome, Italy. 3. Veneto Tumour Registry, Azienda Zero, Padua, Italy. 4. Evaluative Epidemiology Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Registre Bourguignon des Cancers Digestifs, INSERM UMR 1231, CHU de Dijon, Université de Bourgogne, Dijon, France. 6. Editorial Board, Epidemiologia & Prevenzione, Milan, Italy. 7. Registre du Cancer de l'Isère, Grenoble, France. 8. Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, ItalyAzienda Usl della Romagna, Forlì, Italy. 9. National Institute for Health and Medical Research (INSERM), Paris, France. 10. European Commission, Joint Research Centre (JRC), Ispra, Italy. 11. Institute for Research on Population and Social Policies, National Research Council, Rome, Italy. 12. Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 13. Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK. 14. Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy.
Abstract
BACKGROUND: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancer patients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemia patients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanoma patients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. CONCLUSIONS: Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.
BACKGROUND: Few studies have estimated the probability of being cured for cancerpatients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age and period. METHODS: 7.2 million cancerpatients (42 population-based cancer registries in 17 European countries) diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008 were selected from the EUROCARE-5 dataset. Mixture-cure models were used to estimate: (i) life expectancy of fatal cases (LEF); (ii) cure fraction (CF) as proportion of patients with same death rates as the general population; (iii) time to cure (TTC) as time to reach 5-year conditional relative survival (CRS) >95%. RESULTS: LEF ranged from 10 years for chronic lymphocytic leukaemiapatients to <6 months for those with liver, pancreas, brain, gallbladder and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women and 70% in men, 86% for skin melanoma in women and 76% in men, 66% for breast, 63% for prostate and <10% for liver, lung and pancreatic cancers. TTC was <5 years for testis and thyroid cancerpatients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri and melanomapatients of all ages. For breast and prostate cancers, a small excess (CRS < 95%) remained for at least 15 years. CONCLUSIONS: Estimates from this analysis should help to reduce unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.
Authors: Ulrik Ringborg; Anton Berns; Julio E Celis; Manuel Heitor; Josep Tabernero; Joachim Schüz; Michael Baumann; Rui Henrique; Matti Aapro; Partha Basu; Regina Beets-Tan; Benjamin Besse; Fátima Cardoso; Fátima Carneiro; Guy van den Eede; Alexander Eggermont; Stefan Fröhling; Susan Galbraith; Elena Garralda; Douglas Hanahan; Thomas Hofmarcher; Bengt Jönsson; Olli Kallioniemi; Miklós Kásler; Eva Kondorosi; Jan Korbel; Denis Lacombe; José Carlos Machado; José M Martin-Moreno; Francoise Meunier; Péter Nagy; Paolo Nuciforo; Simon Oberst; Júlio Oliveiera; Maria Papatriantafyllou; Walter Ricciardi; Alexander Roediger; Bettina Ryll; Richard Schilsky; Grazia Scocca; Raquel Seruca; Marta Soares; Karen Steindorf; Vincenzo Valentini; Emile Voest; Elisabete Weiderpass; Nils Wilking; Amanda Wren; Laurence Zitvogel Journal: Mol Oncol Date: 2021-09-13 Impact factor: 6.603
Authors: Eric A Engels; Gregory Haber; Allyson Hart; Charles F Lynch; Jie Li; Karen S Pawlish; Baozhen Qiao; Kelly J Yu; Ruth M Pfeiffer Journal: J Clin Oncol Date: 2021-10-22 Impact factor: 50.717
Authors: Mark Lawler; Francesco De Lorenzo; Pernilla Lagergren; Francesco S Mennini; Saronas Narbutas; Grazia Scocca; Françoise Meunier Journal: Mol Oncol Date: 2021-06-15 Impact factor: 6.603
Authors: Ramon Clèries; Maria Buxó; Mireia Vilardell; Alberto Ameijide; José Miguel Martínez; Rebeca Font; Rafael Marcos-Gragera; Montse Puigdemont; Gemma Viñas; Marià Carulla; Josep Alfons Espinàs; Jaume Galceran; Ángel Izquierdo; Josep Maria Borràs Journal: Int J Environ Res Public Health Date: 2022-03-18 Impact factor: 3.390